Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Essa medicao tem mostrado excelentes resultados no tratamento da obesidade e do diabetes tipo 2 , mas seu uso exige prescrio mdica , acompanhamento e monitoramento contnuo para garantir segurana e eficcia
Heterotrimeric GsiN18 was purified by Ni-affinity column and ion-exchange chromatography (44)
Key findings include: SURPASS-1: Tirzepatide at 15 mg reduced HbA1c by 2.07% and body weight by 9.5 kg (approximately 21 lbs) over 40 weeks versus placebo (Rosenstock et al., New England Journal of Medicine , 2021) SURPASS-2: Tirzepatide at 15 mg was superior to semaglutide 1 mg for both HbA1c reduction (2.46% vs 1.86%) and weight loss (12.4 kg vs 6.2 kg) over 40 weeks (Frias et al., New England Journal of Medicine , 2021) SURPASS-4: Tirzepatide demonstrated superiority to insulin glargine for glycemic control with significant weight loss rather than weight gain The SURMOUNT Trials The SURMOUNT program evaluated tirzepatide specifically for weight management in adults without diabetes: SURMOUNT-1: Participants receiving tirzepatide 15 mg lost an average of 22.5% of their body weight (approximately 52 lbs) over 72 weeks, compared to 2.4% for placebo
Why won't my insurance cover it
US$ 21.49
US$ 26.68
US$ 21.81
US$ 21.25
US$ 27.79
